RELMADA THERAPEUTICS INC (RLMD) competitors & alternatives
Health Care · NASDAQ
RELMADA THERAPEUTICS INC (RLMD)'s top competitors and alternatives — its most similar public companies — include NURIX THERAPEUTICS INC (NRIX), VOYAGER THERAPEUTICS INC (VYGR), PROTHENA PLC (PRTA), SOLID BIOSCIENCES INC (SLDB), AGENUS INC (AGEN), KURA ONCOLOGY INC (KURA), HARMONY BIOSCIENCES HLDG INC (HRMY), SIONNA THERAPEUTICS INC (SION), PROTAGONIST THERAPEUTICS INC (PTGX), Neurocrine Biosciences (NBIX), Insmed (INSM) and Roivant Sciences (ROIV). These are RELMADA THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top RLMD competitors & alternatives
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
VOYAGER THERAPEUTICS INCVYGRHealth Care
A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while…
$3.10 (as of 2026-07-22) · market cap $187M
-
PROTHENA PLCPRTAHealth Care
A clinical-stage biotech developing antibody therapies targeting misfolded proteins in Parkinson's disease, Alzheimer's disease, and rare amyloidosis through…
$8.44 (as of 2026-07-22) · market cap $458M
-
SOLID BIOSCIENCES INCSLDBHealth Care
A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's…
$8.10 (as of 2026-07-22) · market cap $808M
-
AGENUS INCAGENHealth Care
A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term…
$5.53 (as of 2026-07-22) · market cap $232M
-
KURA ONCOLOGY INCKURAHealth Care
Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
$10.54 (as of 2026-07-22) · market cap $944M
-
HARMONY BIOSCIENCES HLDG INCHRMYHealth Care
Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor…
$34.86 (as of 2026-07-22) · market cap $2.0B
-
SIONNA THERAPEUTICS INCSIONHealth Care
A clinical-stage biotech pioneering the first drugs to directly stabilize CFTR's NBD1 domain, tackling the "undruggable" target in cystic fibrosis.
$45.03 (as of 2026-07-22) · market cap $2.1B
-
PROTAGONIST THERAPEUTICS INCPTGXHealth Care
Protagonist Therapeutics is a biopharmaceutical firm leveraging a proprietary peptide-based platform to develop targeted therapies for inflammation,…
$135.44 (as of 2026-07-22) · market cap $8.7B
-
Neurocrine BiosciencesNBIXHealth Care
Neurocrine is a profitably growing, neuroscience-focused biotech commercializing novel treatments for movement disorders, endocrine diseases, and psychiatric…
$172.69 (as of 2026-07-22) · market cap $17.8B
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
Roivant SciencesROIVHealth Care
Roivant Sciences is a biopharma-tech incubator that uses a 'Vant' subsidiary model and computational discovery tools to accelerate the development of…
$34.91 (as of 2026-07-22) · market cap $25.1B
Not quite? Describe exactly what you want →
Peers are RELMADA THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: RELMADA THERAPEUTICS INC (RLMD).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.